drugset / Trial / NCT02981940
A Study of Abemaciclib in Recurrent Glioblastoma
Phase 2
Active not recruiting
45 enrolled
Dana-Farber Cancer Institute
Eli Lilly and Company · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
Timeline
- Start
- 2017-02-09
- Primary completion
- 2024-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | — |